Literature DB >> 287555

Biochemical parameters of growth inhibition of human leukemia cells by antitumor anthracycline agents.

H S Schwartz, P M Kanter.   

Abstract

Ten antitumor anthracycline derivatives used in this study inhibit growth of a human leukemia cell line over a range of potencies exceeding four orders of magnitude. The agents vary from each other at C-4 and C-13, with stereochemical differences at C-4' and substitutions at C-14 and N. Drug retention, DNA damage, and inhibition of DNA synthesia are parameters used to express potency of the agents in a mathematic model. Estimates of DNA damage are sufficient, however, to describe growth inhibition by a single agent (4-demethoxydaunorubicin). It may be possible now to attempt to extend the model to predict therapeutic responses to a number of anthracyclines, thereby enhancing the clinical utility of this important class of agents.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 287555

Source DB:  PubMed          Journal:  Cancer Treat Rep        ISSN: 0361-5960


  4 in total

1.  Identification of anthracycline analogues with enhanced cytotoxicity and lack of cross-resistance to adriamycin using a series of mammalian cell lines in vitro.

Authors:  B T Hill; L Y Dennis; X T Li; R D Whelan
Journal:  Cancer Chemother Pharmacol       Date:  1985       Impact factor: 3.333

2.  Comparison of the intracellular pharmacokinetics of doxorubicin and 4'-epi-doxorubicin in patients with acute leukemia.

Authors:  U Tidefelt; B Sundman-Engberg; C Paul
Journal:  Cancer Chemother Pharmacol       Date:  1989       Impact factor: 3.333

3.  Effect of pH and moderate hyperthermia on doxorubicin, epirubicin and aclacinomycin A cytotoxicity for Chinese hamster ovary cells.

Authors:  L Kleeberger; E M Röttinger
Journal:  Cancer Chemother Pharmacol       Date:  1993       Impact factor: 3.333

4.  Intracellular uptake and cytotoxic effect in vitro of doxorubicin and epirubicin in human leukemic and normal hematopoietic cells.

Authors:  U Tidefelt; B Sundman-Engberg; C Paul
Journal:  Cancer Chemother Pharmacol       Date:  1991       Impact factor: 3.333

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.